| A | B | C | D | E | F | G | |
|---|---|---|---|---|---|---|---|
1 | Table 1: Medicare 2016 outlays as reported in CMS Medicare Dashboard, compared to US and global sales* | ||||||
2 | * Note: The Medicare Outlays reported in the CMS Medicare dashboard do not include rebates to manufactures, and thus overstate the net revenue to companies from Medicare sales, sometimes quite a bit, such as for Harvoni. | ||||||
3 | Drug | Company or Companies | Indication | 2016 global sales | US as share of global sales | Medicare dashboard as percent of global | Medicare dashboard as share of US sales |
4 | Xolair (omalizumab) | Genentech/Roche | Asthma and chronic idiopathic urticaria | 1,498CHF | 100% | 27% | 27% |
5 | Perjeta (pertuzumab) | Genentech | Cancer: Breast | CHF1,846 | 49% | 11% | 23% |
6 | Herceptin (trastuzumab) | Roche | Cancer: Breast | CHF6,782 | 37% | 10% | 27% |
7 | Kadcyla (ado-trastuzumab emtansine) | Roche | Cancer: Breast | 831CHF | 38% | 14% | 37% |
8 | Ibrance (palbociclib) | Pfizer | Cancer: Breast | $2,135 | 97% | 47% | 48% |
9 | Afinitor (everolimus) | Novartis | Cancer: Breast/Kidney/Pancreatic; Advanced GI/Lung NET; Renal Angiomyolipoma With Tuberous Sclerosis Complex; SEGA With Tuberous Sclerosis Complex | $1,516 | 51% | 23% | 45% |
10 | Nexavar (sorafenib) | Bayer Healthcare | Cancer: Hepatocellular carcinoma (HCC); renal cell carcinoma (RCC); thyroid carcinoma (DTC) | €870 | 36% | 23% | 65% |
11 | Inlyta (axitinib) | P.F. Prism C.V./Pfizer | Cancer: Kidney | $401 | 40% | 18% | 45% |
12 | Sutent (sunitinib) | Pfizer | Cancer: Kidney; Gastrointestinal Stromal Tumor; Advanced Pancreatic NET | $1,095 | 36% | 17% | 47% |
13 | Tasigna (nilotinib) | Novartis | Cancer: Leukemia | $1,739 | 42% | 18% | 43% |
14 | Gleevec/Glivec (imatinib) | Novartis | Cancer: Leukemia | $3,323 | 37% | 23% | 63% |
15 | Yervoy (ipilimumab) | Bristol-Myers Squibb (BMS) | Cancer: Melanoma | $1,053 | 76% | 22% | 30% |
16 | Zelboraf (vemurafenib) | Hoffman-La Roche | Cancer: Melanoma | 213CHF | 22% | 9% | 40% |
17 | Keytruda (pembrolizumab | Merck | Cancer: Melanoma, NSCLC, HNSCC, cHL | $1,402 | 56% | 0% | 1% |
18 | Revlimid (lenalidomide) | Celgene | Cancer: Multiple myeloma | $6,974 | 63% | 38% | 60% |
19 | Rituxan (rituximab) | Genentech (Roche)/Biogen IDEC | Cancer: non-Hodgkin’s lymphoma; chronic lymphocytic leukemia | 7,300CHF | 54% | 24% | 45% |
20 | Xalkori (crizotinib) | Pfizer | Cancer: Non-Small Cell Lung Cancer | $561 | 45% | 17% | 39% |
21 | Tagrisso (osimertinib) | AstraZeneca | Cancer: Non-Small Cell Lung Cancer | $423 | 60% | 27% | 45% |
22 | Zytiga (abiraterone acetate) | Janssen Biotech | Cancer: Prostate, testicular | $2,260 | 48% | 36% | 76% |
23 | Remicade (infliximab) | Janssen | Crohn's disease; pediatric Crohn's disease; ulcerative colitis; rheumatoid arthritis, psoriatic arthritis; Ankylosing spondylitis; plaque psoriasis | $6,966 | 70% | 20% | 29% |
24 | Orkambi (ivacaftor; lumacaftor) | Vertex Pharmaceuticals | Cystic fibrosis | $980 | 92% | 8% | 9% |
25 | Humalog (insulin lispro recombinant) | Eli Lilly | Diabetes | $2,769 | 61% | 23% | 38% |
26 | Tresiba (insulin degludec) | Novo Nordisk | Diabetes | 4,056 kr. | 55% | 24% | 44% |
27 | Invokana (canagliflozin) | Janssen Pharms | Diabetes | $1,407 | 90% | 43% | 48% |
28 | Fabrazyme (agalsidase beta) | Genzyme | Fabry Disease | €674.0 | 51% | 10% | 20% |
29 | Sovaldi (sofosbuvir) | Gilead | HCV | $4,001 | 47% | 23% | 49% |
30 | Harvoni (ledipasvir; sofosbuvir) | Gilead | HCV | $9,081 | 54% | 48% | 89% |
31 | Complera/Eviplera (emtricitabine; rilviprine hydrochloride; tenofovir disoproxil fumarate) | Gilead | HIV | $1,457 | 56% | 12% | 21% |
32 | Truvada (emtricitabine/tenofovir) | Gilead | HIV | $3,566 | 67% | 18% | 27% |
33 | Atripla (efavirenz/emtricitabine/tenofovir) | Gilead | HIV | $2,605 | 73% | 20% | 28% |
34 | Cymbalta (duloxetine hydrochloride) | Lilly | Major Depressive Disorder | $931 | 29% | 3% | 11% |
35 | Gilenya (fingolimod) | Novartis | Multiple Sclerosis | $2,776 | 61% | 16% | 26% |
36 | Tecfidera (dimethyl fumarate) | Biogen IDEC | Multiple Sclerosis | $3,968 | 80% | 23% | 29% |
37 | Aubagio (teriflunomide) | Sanofi Aventis US | Multiple Sclerosis | €1,295 | 70% | 33% | 47% |
38 | Soliris (eculizumab paroxysmal nocturnal hemoglobinuria) | Alexion | PNH; aHUS | $2,843 | 37% | 10% | 27% |
39 | Lumizyme (alglucosidase alfa) | Sanofi Genzyme | Pompe disease | €725 | 33% | 10% | 30% |
40 | Enbrel (etanercept) | Amgen | Rheumatoid Arthritics; Plaque Psoriasis; Psoriaric Arthritics; Ankylosing Spondylitisl Juvenile Idiopathic Arthritis | $5,965 | 96% | 26% | 27% |
41 | Humira (adalimumab) | Abbvie | Rheumatoid arthritis (initial indication, now many more) | $16,078 | 65% | 14% | 21% |